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Purpose: The purpose of this study was to compare quality of life in patients with and
without various ischemic complications after infrainguinal bypass grafting surgery for
occlusive vascular disease.
Methods: A sample of patients (n = 746) randomized in the Dutch BOA study (n = 2645),
a multicenter trial that compared the effectiveness of oral anticoagulant therapy with
aspirin in the prevention of infrainguinal bypass graft occlusions, was entered in this
study. On the basis of clinical outcomes of the trial, the patients were grouped as fol-
lows: patients with patent grafts (n = 409); patients with nontreated graft occlusions,
subdivided into an asymptomatic group (n = 32) and a symptomatic group (n = 65);
patients with subsequent revascularizations (n = 194); patients with amputations (n =
36); and patients with failed secondary revascularizations followed by secondary ampu-
tation (n = 38). In case an outcome event occurred, the patients were regrouped accord-
ingly. Every half year, the patients completed a Short Form–36 and a EuroQol ques-
tionnaire. A multilevel model was used for repeated measure analysis.
Results: The mean follow-up time was 21 months. The quality of life in patients with
nontreated asymptomatic occlusions was roughly similar to the quality of life in patients
with patent grafts. Patients with symptomatic nontreated occlusions had the lowest out-
come with regard to pain as compared with the other groups. Furthermore, physical and
social functioning was lower for these patients than for patients with patent grafts.
Revascularizations, successful or not, negatively affected pain, social functioning, and
physical and emotional role. After successful revascularization, some improvement was
observed in pain, physical and social functioning, and general and mental health as com-
pared with the group with nontreated symptomatic occlusions. Amputation deteriorat-
ed physical functioning strikingly, especially after failed secondary revascularization.
These patients also had the lowest scores of all the groups in the dimensions of social
functioning, physical and emotional role, and mental health. EuroQol score showed
deterioration of quality of life after all events, except for asymptomatic occlusions. The
same patterns emerged if we stratified our analysis according to the indication for the
initial operation: claudication or limb salvage. Quality of life was constant over time in
all the groups in the observed period.
Conclusion: Quality of life in patients with asymptomatic occluded grafts is similar to
quality of life in patients with patent grafts. Revascularization of symptomatic occluded
grafts improves quality of life to a certain extent. Amputation, in particular after failed
secondary revascularization, seemed to be the lowest possible outcome. The results of
the Short Form-36 and EuroQol measurements were in line with the clinical expecta-
tions. The association of disease severity with scores on the instruments supports the
construct validity of these outcome measures for an objective assessment of quality of
life in controlled studies. (J Vasc Surg 1999;29:913-9.)
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The outcome of infrainguinal bypass grafting
surgery is usually assessed by means of graft patency
and limb salvage. To stimulate standard methods of
reporting, guidelines have been developed.1 From the
point of view of the patients, functional health status is
the most important outcome. So far, only few studies
have added measures of health-related quality of life to
the traditional parameters. Many quality of life instru-
ments have been developed for both clinical and eco-
nomic appraisal. The clinical instruments measure
quality of life from a patient’s point of view. The
instruments used for economic appraisal typically value
the health state for a societal point of view: the health
state of a patient is valued by the general public. Both
kinds of instruments have to be validated before the
scores can be interpreted. The clinical instruments
compare the scores of the patients with the scores of
the other patient groups and the “normal” score of the
general population. The health states measured with
the economic instruments have to be valued by the
general public in large population surveys.
Review of the literature revealed only a few studies
with many different instruments: the Spitzer QL-
Index,2,3 the Short Form-36 (SF-36),4 the Rosser
Scale,5 the Visual Analogue Scale (VAS),6 the mobili-
ty scale,6 the hospital anxiety and depression score,6,7
the Barthel independent activities of daily living
index,6 the Frenchay activities index,6 the environ-
ment score,6 and the social functioning scale.7 Most of
the studies indicated an improved quality of life after
successful bypass grafting surgery and limb salvage.2-7
Only one study, in which the RAND-36-Item Health
Survey (which is comparable to the SF-36) was used,8
did not show a difference in quality of life in 17
patients with patent bypass grafts as compared with
four patients with amputated limbs. Interpretation of
the data from these studies is complicated by the vari-
ety of instruments used and limited by the small num-
bers of patients in the subgroups studied. The SF-36
and the EuroQol are valid, reliable, and widely used
generic questionnaires for measuring quality of life.9-13
Their use has been recommended for quality of life
assessment in patients with vascular disease.14-16
The purpose of this study was to assess quality of
life by means of the SF-36 and EuroQol in patients
with and without various further ischemic complica-
tions after infrainguinal bypass grafting surgery for
occlusive vascular disease.
METHODS
Patients. Between April 1995 and March 1998,
2645 patients were randomized in the Dutch BOA
study (Bypass, Oral anticoagulants, or Aspirin study),17
a multicenter trial that compared the effectiveness of
oral anticoagulant therapy with aspirin in the preven-
tion of occlusions after infrainguinal bypass grafting
surgery. Clinical outcome events in the trial were graft
occlusion, vascular intervention, amputation, myocar-
dial infarction, cerebrovascular accident, and death.
We performed a substudy on quality of life in patients
with different postoperative outcomes. The study was
approved by the Ethics Committees of all the partici-
pating hospitals and by the Dutch Health Insurance
Council. All the patients who were enrolled in the
study gave informed written consent.
From November 1995, a sample of 409 consecu-
tive patients who were included in the trial and who
had had patent grafts and no other outcome event at
the time of the first follow-up examination 3 months
after surgery were included in the present quality of
life study. Furthermore, all the patients with clinical
outcome events in the trial from November 1995
until the last follow-up examination in April 1998
were included in the quality of life study (n = 337).
On the basis of clinical outcomes within the trial, the
746 patients were grouped as follows: patients with
patent grafts and no other outcome events; patients
with nontreated graft occlusions, subdivided into an
occluded asymptomatic group (ie, no claudication in
the concerning leg in patients who initially under-
went operation for claudication and no pain at rest or
ulceration in patients who initially underwent opera-
tion for limb salvage) and an occluded symptomatic
group (ie, claudication or critical ischemia in the con-
cerning leg); and patients with treated graft failures,
subdivided into patients with subsequent revascular-
izations, patients with primary amputations after ini-
tial bypass grafting surgery, and patients with sec-
ondary amputations after failed secondary revascular-
izations. Patients underwent analysis in their initial
group until an outcome event eventually occurred.
In case an outcome event occurred, the patients were
regrouped and underwent analysis from those con-
cerning follow-up examinations in the new groups
accordingly. For example, if a patient was in the
patent graft group during the first and second follow-
up examinations and underwent an amputation dur-
ing the third follow-up period, this patient under-
went analysis twice in the patent graft group and
from the third follow-up examination on in the
amputation group. For a comparison of quality of life
of patients with other severe vascular events, we also
entered patients with myocardial infarctions and
cerebrovascular accidents after the initial operation.
These patients had no other clinical outcome events.
Quality of life measurement. Quality of life was
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measured with the EuroQol and the SF-36 quality of
life questionnaires. The EuroQol instrument consists
of a questionnaire that classifies the patient into one of
243 health states (five dimensions, each with three lev-
els: mobility, self-care, usual activities, pain/discom-
fort, and anxiety/depression). This concise question-
naire generates a single numeric index of health status
between 0 (worst health) and 100 (best health) that
enables calculation of “quality-adjusted life years.”18-20
The societal value of quality of life is obtained.21 This
societal perspective is the preferred perspective in an
economic evaluation of health care. The EuroQol also
contains a VAS on which patients rate their own health
between 0 and 100. This value represents the patients’
perspective and is considered as the clinical perspective
of quality of life. The EuroQol generates two overall
values (utilities) for the quality of life (one from soci-
etal and one from the patients’ perspective) and is rec-
ommended for use in combination with other more
detailed generic measures, such as the SF-36.9,11 The
SF-36 contains 36 questions that cover the following
eight dimensions of health: pain, physical functioning,
social functioning, physical role, emotional role, men-
tal health, general health, and vitality. It produces a
health profile with scores between 0 and 100 for each
dimension. A high score indicates good health status
from the patient’s perspective.
Every 6 months, the patients were asked to com-
plete the EuroQol and the SF-36 quality of life ques-
tionnaires. The questionnaires were sent by mail to all
the patients. Incomplete questionnaires were returned
to the patients for completion. If necessary, the miss-
ing questions were completed with a telephone call.
Because the inclusion of the patients in this study con-
tinued until the moment of analysis (May 1998), the
first patients included completed more questionnaires
than those patients who were included last.
Statistical analysis. In longitudinal studies of
quality of life, the usual statistical test applied is a
repeated measure analysis. However, this test is not
suitable when the number of observations varies with
patients and when the same patients undergo analy-
sis in different groups, which was the case in the pres-
ent study. Therefore, we used a relatively new statis-
tical method called multilevel modeling that allows
repeated measures analysis with an unequal number
of observations per patient.22 A pivotal assumption
for multilevel models is that the number of observa-
tions is independent of the outcome (ie, quality of
life). In the design of the study, this condition is ful-
filled because the number of observations is deter-
mined by the inclusion of patients over time, inde-
pendent of the quality of life of the patients.
The recognition that quality of life must be seen
as a multidimensional phenomenon and the large
number of relevant clinical groups led to multiple
comparisons of results. This large number of com-
parisons complicated the formal statistical testing of
the results. We therefore chose to present the results
in an explorative fashion as mean values, with the
corresponding unbiased 95% confidence intervals as
calculated with the multilevel model, which then was
interpreted with caution. This presentation was also
in line with the observational nature of the quality of
life measurement.
RESULTS
The mean age of the 746 patients who were
included in the study was 70 years, with most
patients being men (64%). In 341 patients (46%),
the indication for surgery at study entry was inter-
mittent claudication, and 405 patients (54%) under-
went operation for critical ischemia.
The mean follow-up period was 21 months. The
number of patients in each group and the propor-
tion of patients who underwent operation for clau-
dication are given in the two left columns of Table I.
The number of questionnaires that were completed
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Table I. Number of patients, indications for initial surgery, and completed questionnaires in each group
No. of questionnaires 
Group No. of patients Claudication* (%) No. of questionnaires per patient
Patent graft 409 48 1612 3.9
Asymptomatic occlusion 32 47 96 3
Symptomatic occlusion 65 62 243 3.7
Revascularization 194 49 712 3.7
Primary amputation 36 6 124 3.4
Secondary amputation 38 18 126 3.3
Myocardial infarction 16 31 58 3.6
Cerebrovascular accident 25 52 82 3.3
*Indication for bypass grafting surgery at baseline; in the remaining patients the indication was limb salvage.
by each group is presented in the right part of Table
I. Because of the occurrence of a clinical outcome,
patients entered subsequent groups 69 times.
The number of missing values was small: only 64
patients (8.6%) of those included did not complete
one or more questionnaires. The following reasons
were mentioned: not interested (n = 22), too emo-
tional (n = 21; 8 patients because of amputation),
unable because of dementia (n = 5), unable because of
stroke (n = 2), other (n = 3), and unknown (n = 11).
Quality of life results, subdivided over eight
dimensions of the SF-36, are shown in Fig 1. Quality
of life in patients with nontreated asymptomatic
occlusions was roughly similar to quality of life in
patients with patent grafts, with a tendency for lower
values in the physical domains for the first group.
The patients with clinically symptomatic nontreated
occlusions had the lowest scores with regard to pain.
Furthermore, their physical and social functioning
appeared to be less than that in patients with patent
grafts. After secondary revascularizations, successful
or not, the scores for pain, social functioning, and
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Fig 1. Mean values (squares) with corresponding 95% confidence intervals of SF-36 domains
for each of the clinical outcome groups.
physical and emotional role were lower than those
scores in patients with patent grafts or with asympto-
matic occlusions. However, after successful revascu-
larization, some improvement was observed in pain,
physical and social functioning, and general and
mental health as compared with the group with non-
treated symptomatic occlusions. In patients after
amputation, low scores in the physical functioning
domain were reported, especially after failed sec-
ondary revascularization. These patients also had the
lowest scores of all the groups in the dimensions of
social functioning, physical and emotional role, and
mental health. A difference in the extent of disease
was seen between the latter two groups. In the pri-
mary amputation group, 16 of the 36 cases were
transmetatarsal or Syme’s amputations, whereas in
the secondary amputation group, there was only one
transmetatarsal amputation and 37 below-knee,
through-knee, and above-knee amputations (with c 2
test, P = .00002; Table II). After myocardial infarc-
tion and stroke, general health and vitality most
clearly were deteriorated.
The results of the EuroQol scores are presented
in Fig 2. Both unidimensional measures of quality of
life confirmed the findings of the multidimensional
measures from the SF-36. Quality of life of patients
with asymptomatic occlusions did not essentially dif-
fer from quality of life of patients with patent grafts.
However, quality of life was lower after the other
outcomes. The quality of life as valued by the patients
themselves on the VAS was higher than the values
that were given to health status by the general public
(ie, the societal value).
Quality of life in all groups, in all domains of the
SF-36, and in the societal perspective of the EuroQol
was lower for patients who initially underwent oper-
ation for limb salvage as compared with those who
underwent operation for claudication. On the con-
trary, the VAS scores of patients with asymptomatic
occlusions were higher in the patients who entered
the study with critical ischemia as compared with the
patients with claudication at baseline. In all groups
and in all domains of SF-36 and in EuroQol, quality
of life was essentially constant over time after the ini-
tial procedure.
DISCUSSION
This study was conducted to describe the obser-
vational differences of quality of life after graft occlu-
sion, reoperations, and amputations in patients who
had undergone infrainguinal bypass grafting surgery.
In most domains of the SF-36 and EuroQol, the
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Table II. Levels of amputations
Primary amputation Secondary amputation
Amputation level group (n = 36) group (n = 38)
Transmetatarsal 15 (41.7%) 1 (2.6%)
Syme’s 1 (2.8%) 0
Below knee 12 (33.3%) 25 (65.8%)
Through knee 4 (11.1%) 3 (7.9%)
Above knee 4 (11.1%) 9 (23.7%)
Fig 2. Mean values (squares) with corresponding 95% confidence intervals of EuroQol for
each of the clinical outcome groups. VAS, visual analogue scale.
patients with patent grafts had the highest quality of
life. Quality of life in patients with clinically asympto-
matic graft occlusions was nearly similar as compared
with quality of life in patients with patent grafts.
Patients with symptomatic occlusions, on the other
hand, had a lower quality of life as compared with
patients with patent grafts, particularly with regard to
pain. After revascularization of symptomatic occluded
grafts, a tendency toward improved quality of life 
was observed: improvement was seen in six of the
eight domains of SF-36 and in the EuroQol score.
Amputation deteriorated quality of life in all domains,
except for pain, which makes an attempt for revascu-
larization, particularly in patients with critical
ischemia, worth the effort. Failed revascularization
that resulted in secondary amputation, however, had
a dramatic impact on the deterioration of quality of
life. The differences between the studied groups strat-
ified for indication for initial operation at study entry
revealed approximately the same results as for the
reported overall groups of patients, except for the
VAS score in the patients with patent grafts and with
asymptomatic occlusion.
Quality of life of the patients for vascular surgery
was in all domains far lower than in the healthy pop-
ulation, which had scores from a minimum of 61
(general) to a maximum of 84 (physical function-
ing).13 This implies that the measured quality of life
is a result of vascular disease and is not easily
explained with comorbid factors.
In this prospective study, the number of patients in
the groups with ischemic complications was relatively
small, which resulted in wide confidence intervals.
These intervals should be interpreted with caution
when multiple comparisons of results are made. The
mean scores are observational values of quality of life.
Missing data that may have been related to poor
quality of life possibly induced bias. The number of
patients who failed to complete one or more ques-
tionnaires was low in this group of elderly patients
(8.6%). These patients were equally distributed over
the various groups.
The aim of this observational study was to mea-
sure quality of life in patients with different clinical
outcomes after infrainguinal bypass grafting surgery.
Therefore, possible differences in comorbid condi-
tions between the studied groups were not consid-
ered. However, the influence of the most important
risk factor on the quality of life, indication for the
initial operation, was assessed. The similarity of qual-
ity of life between all patients with patent grafts and
with asymptomatic occluded grafts was stratified in
the analysis for indication for initial operation not
consistent in the VAS score. The VAS score repre-
sented the subjective value of quality of life from the
perspective of a patient. It therefore seems likely that
the better quality of life in patients who underwent
operation for limb salvage is caused by coping mech-
anisms as a result of achieved limb salvage. The sim-
ilarity in all other domains between patients in the
patent graft and asymptomatic occlusion groups
might be explained by effects of conservative treat-
ment, such as walking exercises.
The lower quality of life in patients with sympto-
matic occlusions cannot be explained by a difference
in severity of disease at study entry because 62% of
the patients with symptomatic occlusions underwent
operation for claudication, in contrast with the group
with asymptomatic occlusions, in which the indica-
tion for surgery was claudication in only 47%. The
differences in quality of life between the patients with
asymptomatic and symptomatic occlusions and also
in the primary and secondary amputation groups
may be explained by the difference in the severity of
the disease between the groups at the time of mea-
suring quality of life. Because transmetatarsal ampu-
tations produce less disability than do higher ampu-
tations, it is likely that these patients contributed to
the higher score of quality of life in the primary
amputation group. The association of disease severi-
ty with scores on the instruments used can be con-
sidered as convergence validity, which supports the
construct validity of the SF-36 and EuroQol in this
population.23 The good relation between symptoms
as a result of graft occlusion as assessed by the clini-
cian and functional health status as experienced by
the patient affirms the good responsiveness of the SF-
36 and EuroQol score to increasing limb ischemia as
also seen in studies by Chetter et al.15,24
Results of infrainguinal bypass grafting surgery are
usually reported as graft patency, sometimes supple-
mented by change of ankle pressure, clinical descrip-
tion, and walking distance, with the latter two giving
some information about pain and physical functioning.
However, functional health status concerns more than
these two clinical measures reported from the doctor’s
perspective. To compare quality of life in different cat-
egories of patients and to compare results of different
studies, it is recommendable to use standard instru-
ments, such as SF-36 and EuroQol. In addition to the
SF-36, we used EuroQol because it permits one to
measure the societal perspective of quality of life. This
is the preferred perspective in the future cost-effective-
ness analyses.19 The results on the two EuroQol scores
indicate that quality of life as valued by the patients
themselves was higher than that assessed by the gener-
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al public. This is a common finding and usually is
interpreted as a result of coping mechanisms. The
inclusion of coping effects in the patients’ value of
quality of life is one of the reasons not to use these val-
ues but societal values for economic appraisal.20
The occurrence of failure of an arterial recon-
struction triggers a complex process of decision mak-
ing, which is influenced and directed by clinical symp-
toms, risk factors, anatomic situations, and technical
aspects of surgery and experience, and results in a
choice of treatment. Besides improvement of clinical
symptoms and limb salvage, a satisfactory quality of
life should be the goal of treatment. Knowledge of
functional health prospects in various categories of
patients is therefore indispensable. This study showed
similar quality of life in patients with asymptomatic
occluded grafts as compared with patients with patent
grafts. Revascularization of symptomatic occluded
grafts improves quality of life to a certain extent.
Amputation, however, in particular after failed sec-
ondary revascularization, seems to be the lowest pos-
sible outcome. As far as quality of life is concerned,
this sequence of events has to be avoided by optimal
patient selection.
The low quality of life and the extensive use of
resources necessary for management of patients for
vascular surgery, especially after failed bypass grafting
surgery, justify profound decision analytic research.
The multilevel model is a suitable tool for analyzing
these type of data with various numbers of observa-
tions over time and with patients measured in various
groups because they incorporate only repeated mea-
sure models but allow for skipped measurements.
The good responsiveness of the SF-36 and EuroQol
to events in patients for vascular surgery pleads for
widespread use of these instruments as valid and
objective outcome measures besides the traditional
clinical outcomes in controlled studies.
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